Triple reuptake inhibitors for treating subtypes of major depressive disorder: the monoamine hypothesis revisited (Q37891098)

24 August 2017

1 reference

title

Triple reuptake inhibitors for treating subtypes of major depressive disorder: the monoamine hypothesis revisited (English)

1 reference

major depressive disorder

24 August 2017

main subject

1 reference

Jolanda Prins

1

1 reference

24 August 2017

Berend Olivier

series ordinal

2

1 reference

24 August 2017

S Mechiel Korte

series ordinal

3

1 reference

24 August 2017

language of work or name

English

0 references

publication date

20 June 2011

1 reference

Expert Opinion on Investigational Drugs

24 August 2017

published in

1 reference

24 August 2017

volume

20

1 reference

24 August 2017

issue

8

1 reference

24 August 2017

page(s)

1107-1130

1 reference

Using epidemiological data to model efficiency in reducing the burden of depression*

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Current investigational drugs for major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Relevance of norepinephrine-dopamine interactions in the treatment of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Role of serotonin in central dopamine dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

The role of dopamine in the pathophysiology of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Preclinical and clinical pharmacology of DOV 216,303, a "triple" reuptake inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

"Broad spectrum" antidepressants: is more better for the treatment of depression?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

The validity of major depression with atypical features based on a community study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Identifying depressive subtypes in a large cohort study: results from the Netherlands Study of Depression and Anxiety (NESDA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Organization of the stress system and its dysregulation in melancholic and atypical depression: high vs low CRH/NE states

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

The endocrinology of melancholic and atypical depression: relation to neurocircuitry and somatic consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Reversed neurovegetative symptoms of depression: a community study of Ontario

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Antidepressant drug effects and depression severity: a patient-level meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Subtyping major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

The prefrontal cortex--an update: time is of the essence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Neurocircuitry of mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Neural and behavioral substrates of mood and mood regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

The functional neuroanatomy of depression: distinct roles for ventromedial and dorsolateral prefrontal cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Neurocircuitry of addiction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

The neuropsychopharmacology of fronto-executive function: monoaminergic modulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Activation of an inhibitory noradrenergic pathway projecting from the locus coeruleus to the cingulate cortex of the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

The locus coeruleus–noradrenergic system: modulation of behavioral state and state-dependent cognitive processes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Through the looking glass: differential noradenergic modulation of prefrontal cortical function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Pronounced and sustained central hypernoradrenergic function in major depression with melancholic features: relation to hypercortisolism and corticotropin-releasing hormone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Widespread origin of the primate mesofrontal dopamine system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Unfaithful neurotransmitter transporters: focus on serotonin uptake and implications for antidepressant efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Affective neuroscience of pleasure: reward in humans and animals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Interaction between glucocorticoid hormones, stress and psychostimulant drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Antiinflammatory action of glucocorticoids--new mechanisms for old drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Drugs of abuse and the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Probing brain reward system function in major depressive disorder: altered response to dextroamphetamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Functional neuroanatomical substrates of altered reward processing in major depressive disorder revealed by a dopaminergic probe

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

The need to feed: homeostatic and hedonic control of eating

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Eating for pleasure or calories

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Dopamine D2 receptors in addiction-like reward dysfunction and compulsive eating in obese rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Hypothalamic and extrahypothalamic substrates of predatory attack. Suppression and the influence of hunger

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

A commentary on the neurobiology of the hypocretin/orexin system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

The sleep switch: hypothalamic control of sleep and wakefulness

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

The melanin-concentrating hormone system of the rat brain: an immuno- and hybridization histochemical characterization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Extracellular histamine levels in the feline preoptic/anterior hypothalamic area during natural sleep-wakefulness and prolonged wakefulness: an in vivo microdialysis study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Coadministration of modafinil and a selective serotonin reuptake inhibitor from the initiation of treatment of major depressive disorder with fatigue and sleepiness: a double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Modafinil increases histamine release in the anterior hypothalamus of rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Resolution of sleepiness and fatigue in major depressive disorder: A comparison of bupropion and the selective serotonin reuptake inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Abnormal speech articulation, psychomotor retardation, and subcortical dysfunction in major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Correlation between cerebrospinal fluid amine metabolites and psychomotor activity in affective disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Depressive psychomotor disturbance, cortisol, and dexamethasone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Decreased presynaptic dopamine function in the left caudate of depressed patients with affective flattening and psychomotor retardation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Dopaminergic function in depressed patients with affective flattening or with impulsivity: [18F]fluoro-L-dopa positron emission tomography study with voxel-based analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

21 January 2018

Serotonin and aggression

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Tonic and phasic alteration in amygdala 5-HT, glutamate and GABA transmission after prefrontal cortex damage in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Adrenocortical hyperactivity in depression: Effects of agitation, delusions, melancholia, and other illness variables

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Suicide: a four-pathway clinical-biochemical model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Reduced dopaminergic activity in depressed suicides.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Hypothalamic-pituitary-adrenal axis function and suicidal behavior in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Structural and cognitive deficits in remitting and non-remitting recurrent depression: a voxel-based morphometric study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

The roles of prefrontal brain regions in components of working memory: effects of memory load and individual differences

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

From real-world events to psychosis: the emerging neuropharmacology of delusions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Depression and hypothalamic-pituitary-adrenal activation: a quantitative summary of four decades of research

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Characterization of the antinociceptive actions of bicifadine in models of acute, persistent, and chronic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Current and historical concepts of opiate treatment in psychiatric disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

The treatment of depressive states with G 22355 (imipramine hydrochloride).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Effect of psychotropic drugs on the uptake of H3-norepinephrine by tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Selegiline transdermal system: a novel treatment option for major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

The catecholamine hypothesis of affective disorders: a review of supporting evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Cross-talk between dopaminergic and noradrenergic systems in the rat ventral tegmental area, locus ceruleus, and dorsal hippocampus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Prospect of a dopamine contribution in the next generation of antidepressant drugs: the triple reuptake inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Sequential improvement of anxiety, depression and anhedonia with sertraline treatment in patients with major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

The many faces of fatigue in major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Effect of continuation treatment on residual symptoms in late-life depression: how well is "well"?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Symptom-based predictors of a 10-year chronic course of treated depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

A meta-analysis of clinical trials comparing reboxetine, a norepinephrine reuptake inhibitor, with selective serotonin reuptake inhibitors for the treatment of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

The mesolimbic dopamine reward circuit in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

The other face of depression, reduced positive affect: the role of catecholamines in causation and cure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Conceptualization and measurement of quality of life in dementia: the dementia quality of life instrument (DQoL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Ropinirole in treatment-resistant depression: a 16-week pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Potentiation by low doses of selected neuroleptics of food-induced conditioned place preference in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Effects of the dopamine agonist pramipexole on depression, anhedonia and motor functioning in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Bupropion as the treatment of choice in depression associated with Parkinson's disease and it's various treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Dopamine, but not norepinephrine or serotonin, reuptake inhibition reverses motor deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Dopamine signals for reward value and risk: basic and recent data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Multiple Dopamine Functions at Different Time Courses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Afferent modulation of dopamine neuron firing differentially regulates tonic and phasic dopamine transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

A common neurobiology for pain and pleasure

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Functional antagonists at the NMDA receptor complex exhibit antidepressant actions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

GABAergic dysfunction in mood disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Antidepressant mechanisms: functional and molecular correlates of excitatory amino acid neurotransmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Dysregulation in the suicide brain: mRNA expression of corticotropin-releasing hormone receptors and GABA(A) receptor subunits in frontal cortical brain region.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Don't worry 'B' happy!: a role for GABA(B) receptors in anxiety and depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

The neurobiological properties of tianeptine (Stablon): from monoamine hypothesis to glutamatergic modulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

NMDA glutamatergic receptors, labelled with [3H]MK-801, in brain samples from drug-free depressed suicides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Global brain gene expression analysis links glutamatergic and GABAergic alterations to suicide and major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Neuroimaging studies of mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Antidepressant treatments and function of glutamate ionotropic receptors mediating amine release in hippocampus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Regulation of cellular plasticity cascades in the pathophysiology and treatment of mood disorders: role of the glutamatergic system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Fluoxetine depresses glutamate exocytosis in the rat cerebrocortical nerve terminals (synaptosomes) via inhibition of P/Q-type Ca2+ channels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Chronic antidepressants reduce depolarization-evoked glutamate release and protein interactions favoring formation of SNARE complex in hippocampus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Inhibition of glutamate release by bupropion in rat cerebral cortex nerve terminals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Repeated administration of imipramine attenuates glutamatergic transmission in rat frontal cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Evidence for increased expression of the vesicular glutamate transporter, VGLUT1, by a course of antidepressant treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Selective cortical VGLUT1 increase as a marker for antidepressant activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Adaptation of the NMDA receptor in rat cortex following chronic electroconvulsive shock or imipramine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Adaptation of N-methyl-D-aspartate (NMDA) receptors following antidepressant treatment: implications for the pharmacotherapy of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Adaptation of cortical NMDA receptors by chronic treatment with specific serotonin reuptake inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Rapid increase in PKA activity during long-term potentiation in the hippocampal afferent fibre system to the prefrontal cortex in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Dopamine: a potential substrate for synaptic plasticity and memory mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Interaction of dopamine D1 with NMDA NR1 receptors in rat prefrontal cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

A new strategy for antidepressant prescription

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Dopamine receptors regulate NMDA receptor surface expression in prefrontal cortex neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Regulation of editing and expression of glutamate alpha-amino-propionic-acid (AMPA)/kainate receptors by antidepressant drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Involvement of striatal and extrastriatal DARPP-32 in biochemical and behavioral effects of fluoxetine (Prozac).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Neuronal proteins involved in synaptic targeting of AMPA receptors in rat hippocampus by antidepressant drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Dopamine receptor stimulation modulates AMPA receptor synaptic insertion in prefrontal cortex neurons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Medication augmentation after the failure of SSRIs for depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Bupropion occupancy of the dopamine transporter is low during clinical treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

The putative antidepressant DOV 216,303, a triple reuptake inhibitor, increases monoamine release in the prefrontal cortex of olfactory bulbectomized rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

The novel triple reuptake inhibitor JZAD-IV-22 exhibits an antidepressant pharmacological profile without locomotor stimulant or sensitization properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

The potential and limitations of DOV 216,303 as a triple reuptake inhibitor for the treatment of major depression: A microdialyis study in olfactory bulbectomized rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Onset and early behavioral effects of pharmacologically different antidepressants and placebo in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Is the forced swimming test a suitable model for revealing antidepressant activity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Neurobehavioral studies of forced swimming: the role of learning and memory in the forced swim test

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Pathophysiology of depression: do we have any solid evidence of interest to clinicians?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Corticosteroids in relation to fear, anxiety and psychopathology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Emotional memory systems in the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Animal models of anxiety and their molecular dissection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Intermittent and continuous swim stress-induced behavioral depression: sensitivity to norepinephrine- and serotonin-selective antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

The validity of animal models of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Chronic mild stress-induced anhedonia: a realistic animal model of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Neonatal maternal separation exacerbates the reward-enhancing effect of acute amphetamine administration and the anhedonic effect of repeated social defeat in adult rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Housing familiar male wildtype rats together reduces the long-term adverse behavioural and physiological effects of social defeat

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Construct validity of a self-stimulation threshold paradigm: Effects of reward and performance manipulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Reduction of sucrose preference by chronic unpredictable mild stress, and its restoration by a tricyclic antidepressant

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

A new female rat animal model for hypoactive sexual desire disorder; behavioral and pharmacological evidence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Long-term behavioral changes after cessation of chronic antidepressant treatment in olfactory bulbectomized rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

The corticosteroid receptor hypothesis of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

From inflammation to sickness and depression: when the immune system subjugates the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Mesolimbic dopaminergic mechanisms and pain control

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Psychostimulant-like discriminative stimulus and locomotor sensitization properties of the wake-promoting agent modafinil in rodents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Characterization of nicotine's ability to serve as a negative feature in a Pavlovian appetitive conditioning task in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Preclinical evaluation of the abuse potential of the analgesic bicifadine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Acute doses of d-amphetamine and bupropion increase cigarette smoking

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Subjective effects of slow-release bupropion versus caffeine as determined in a quasi-naturalistic setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Subjective and objective effects of the novel triple reuptake inhibitor tesofensine in recreational stimulant users

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Relationship between subjective effects of cocaine and dopamine transporter occupancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

A slow-onset, long-duration indanamine monoamine reuptake inhibitor as a potential maintenance pharmacotherapy for psychostimulant abuse: effects in laboratory rat models relating to addiction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Subgenual prefrontal cortex abnormalities in mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

The cellular neurobiology of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for Difficult-to-Treat depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Molecular mechanisms of neuroplasticity and pharmacological implications: the example of tianeptine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Stress, depression, and neuroplasticity: a convergence of mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

From high anxiety trait to depression: a neurocognitive hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

The possibility of neurotoxicity in the hippocampus in major depression: a primer on neuron death

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Rapid glucocorticoid effects on excitatory amino acid levels in the hippocampus: a microdialysis study in freely moving rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Rapid changes in hippocampal CA1 pyramidal cell function via pre- as well as postsynaptic membrane mineralocorticoid receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Mineralocorticoid receptors are indispensable for nongenomic modulation of hippocampal glutamate transmission by corticosterone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Acute stress enhances glutamatergic transmission in prefrontal cortex and facilitates working memory

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Synthesis and pharmacological evaluation of 3-aryl-3-azolylpropan-1-amines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Triple Reuptake Inhibitors: A Premise and Promise

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Effect of DOV 102,677 on the volitional consumption of ethanol by Myers' high ethanol-preferring rat

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

The triple monoaminergic reuptake inhibitor DOV 216,303 has antidepressant effects in the rat olfactory bulbectomy model and lacks sexual side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

DOV 216,303, a "triple" reuptake inhibitor: safety, tolerability, and pharmacokinetic profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Triple uptake inhibitors: therapeutic potential in depression and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Triple reuptake inhibitors ("broad spectrum" antidepressants).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Characterization of the electrophysiological properties of triple reuptake inhibitors on monoaminergic neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Antidepressant-like actions of DOV 21,947: a "triple" reuptake inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

The novel triple monoamine reuptake inhibitor tesofensine induces sustained weight loss and improves glycemic control in the diet-induced obese rat: comparison to sibutramine and rimonabant

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Expression of brain derived neurotrophic factor, activity-regulated cytoskeleton protein mRNA, and enhancement of adult hippocampal neurogenesis in rats after sub-chronic and chronic treatment with the triple monoamine re-uptake inhibitor tesofensine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations: the ADVANS Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

In-vitro and in-vivo characterization of JNJ-7925476, a novel triple monoamine uptake inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Pyrroloisoquinoline antidepressants. 2. In-depth exploration of structure-activity relationships

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Antidepressant-like effects of novel triple reuptake inhibitors, PRC025 and PRC050.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Antidepressant-like pharmacological profile of a novel triple reuptake inhibitor, (1S,2S)-3-(methylamino)-2-(naphthalen-2-yl)-1-phenylpropan-1-ol (PRC200-SS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Novel 3,3-disubstituted pyrrolidines as selective triple serotonin/norepinephrine/dopamine reuptake inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

2-Substituted N-aryl piperazines as novel triple reuptake inhibitors for the treatment of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

1-(Aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes and 6-(aryl)-6-[alkoxyalkyl]-3-azabicyclo[3.1.0]hexanes: a new series of potent and selective triple reuptake inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Potencies of cocaine methiodide on major cocaine targets in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Comparison of the effects of antidepressants and their metabolites on reuptake of biogenic amines and on receptor binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Pharmacological profile of antidepressants and related compounds at human monoamine transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Neural systems of reinforcement for drug addiction: from actions to habits to compulsion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Comparative studies with milnacipran and tricyclic antidepressants in the treatment of patients with major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

Milnacipran and selective serotonin reuptake inhibitors in major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594039

10.1517/13543784.2011.594039

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference